Clinical Trials Logo

Clinical Trial Details — Status: Temporarily not available

Administrative data

NCT number NCT05221619
Other study ID # CR109152
Secondary ID 80202135WHA4001
Status Temporarily not available
Phase
First received
Last updated

Study information

Verified date January 2024
Source Janssen Research & Development, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

The purpose of this post-trial access (PTA) program is to provide nipocalimab for the treatment of participants with Warm Autoimmune Hemolytic Anemia (wAIHA) who are experiencing clinical benefit after completing 28-weeks open-label extension in MOM-M281-006 (NCT04119050) study.


Recruitment information / eligibility

Status Temporarily not available
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Participants demonstrate clinical benefit (improvement of hemoglobin from baseline) at the Week 28 assessment in the open-label extension of the MOM-M281-006 (NCT04119050) study - Participants does not have co-morbidities that would alter the risk-benefit of nipocalimab administration (determined by treating physician) - Participants completed treatment in the 28-week open-label extension of the MOM-M281-006 (NCT04119050) study without receiving rescue treatment or discontinuation of the study prior to Week 28 visit Exclusion Criteria: - Participants have a serious or clinically significant infection (example: pneumonia, biliary tract infection, diverticulitis, Clostridioides difficile infection) requiring parenteral anti-infectives and/or hospitalization - Participants have a chronic infection (example: bronchiectasis, chronic osteomyelitis, chronic pyelonephritis) or require chronic treatment with anti-infectives (example: antibiotics, antivirals)

Study Design


Intervention

Drug:
Nipocalimab
Depending on the dose received at their last administration in the MOM-M281-006 (NCT04119050) study, participants will continue to receive either nipocalimab dose-1 every 2 weeks (Q2W) or nipocalimab dose-2 every 4 weeks (Q4W) by intravenous (IV) infusion.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Janssen Research & Development, LLC
See also
  Status Clinical Trial Phase
Recruiting NCT05786573 - A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) Phase 3
Withdrawn NCT03965624 - Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia Phase 2
Recruiting NCT05922839 - Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA Phase 2
Completed NCT01181154 - Rituximab in Auto-Immune Hemolytic Anemia Phase 3
Recruiting NCT05925023 - Sirolimus in the Treatment of Refractory/Relapsed wAIHA Phase 2
Recruiting NCT05757570 - An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias Phase 1/Phase 2
Withdrawn NCT04256148 - ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia Phase 2
Terminated NCT03075878 - A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) Phase 1/Phase 2
Withdrawn NCT04956276 - Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia Phase 2
Completed NCT03226678 - Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) Phase 2
Recruiting NCT04119050 - Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia Phase 2/Phase 3
Terminated NCT04253236 - To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). Phase 2